Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy.
胰高血糖素和糖尿病微血管併發症:神經病變、腎病變、視網膜病變和微血管病變。
Diabetologia 2023-09-28
DPP-4 Inhibitors Suppress Tau Phosphorylation and Promote Neuron Autophagy through the AMPK/mTOR Pathway to Ameliorate Cognitive Dysfunction in Diabetic Mellitus.
DPP-4 抑制劑透過 AMPK/mTOR 途徑抑制 Tau 磷酸化並促進神經元自噬,以改善糖尿病性認知功能障礙。
ACS Chem Neurosci 2023-09-21
Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson's disease in diabetic patients.
糖尿病患者使用二肽基胜肽酶-4抑制劑與帕金森病風險降低相關。
Sci Rep 2023-12-28
Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy.
糖尿病周邊神經病變管理的葡萄糖樣肽-1 受體激動劑。
Front Endocrinol (Lausanne) 2024-02-29
Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review.
二胺基肽酶4抑制劑對阿茲海默症的神經保護作用:敘事性綜述。
Front Pharmacol 2024-02-27
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease.
DPP-4 抑制劑 sitagliptin 和 PF-00734,200 在大鼠 6-OHDA 帕金森氏症模型中緩解多巴胺能神經退化、神經炎症和行為障礙。
Geroscience 2024-04-02
Effect of New Antidiabetics on Steatosis in Nerve Tissues and Nerve Conduction Velocity: Possible Role of Nerve Growth Factor (NGF)/Synaptophysin and Nrf2/HO-1 Pathways.
新型抗糖尿病藥物對神經組織脂肪變性及神經傳導速度的影響:神經生長因子 (NGF)/突觸素和Nrf2/HO-1途徑的可能角色。
Cureus 2024-08-30